The Technical Analyst
Verona Pharma plc [VRNA]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Verona Pharma plc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
0.46% $15.31
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 231.57 mill |
| EPS: | -0.720 |
| P/E: | -21.26 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 80.44 mill |
| Avg Daily Volume: | 0.439 mill |
| RATING 2024-04-25 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | |
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -21.26 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -3.62x |
| Company: PE -21.26 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$3.48 (-77.26%) $-11.83 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 14.51 - 16.11 ( +/- 5.20%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-01 | Fisher Andrew | Buy | 2 400 000 | Share Options (Right to Buy) |
| 2024-03-04 | Fisher Andrew | Buy | 0 | |
| 2024-02-01 | Zaccardelli David | Sell | 480 200 | Ordinary Shares |
| 2024-02-01 | Rickard Kathleen A. | Sell | 72 768 | Ordinary Shares |
| 2024-02-05 | Rickard Kathleen A. | Sell | 36 248 | Ordinary Shares |
| INSIDER POWER |
|---|
| -13.44 |
| Last 97 transactions |
| Buy: 7 137 944 | Sell: 12 997 482 |
Forecast:
16:00 - $15.31
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $15.31
Forecast 2: 16:00 - $15.31
Forecast 3: 16:00 - $15.31
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $15.31 (0.46% ) |
| Volume | 0.494 mill |
| Avg. Vol. | 0.439 mill |
| % of Avg. Vol | 112.54 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VRNA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $16.25 | N/A | Active |
|---|
VRNA
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Last 10 Buy Signals
Latest Press Releases
2024-04-25 02:00:00 - Press Release
Verona Pharma To Report First Quarter 2024 Financial Results And Provide Corporate Update
London and raleigh, n.c., april 25, 2024 (globe newswire) -- verona pharma plc (nasdaq: vrna) (“verona pharma” or the “company”) announces that it will report its financial results for the first quarter ended march 31, 2024 on thursday, may 9, 2024 and host an investment community conference call at 9:00 a.m. edt / 2:00 p.m. bst to discuss these financial results and provide a corporate update.
2024-03-04 02:00:00 - Press Release
Andrew Fisher Joins Verona Pharma As General Counsel
London and raleigh, n.c., march 04, 2024 (globe newswire) -- verona pharma plc (nasdaq: vrna) (“verona pharma” or the “company”), announces mr.
2024-02-29 02:00:00 - Press Release
Verona Pharma Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Corporate Update
Pdufa target action date for ensifentrine of june 26, 2024 commercialization preparations advance strong balance sheet supports commercialization and company's growth conference call today at 9:00 a.m. est / 2:00 p.m.
2024-02-15 02:00:00 - Press Release
Verona Pharma To Report Fourth Quarter And Full Year 2023 Financial Results And Provide Corporate Update
London and raleigh, n.c., feb. 15, 2024 (globe newswire) -- verona pharma plc (nasdaq: vrna) (“verona pharma” or the “company”) announces that it will report its financial results for the fourth quarter and full year ended december 31, 2023 on thursday, february 29, 2024 and host an investment community conference call at 9:00 a.m. est / 2:00 p.m. gmt to discuss these financial results and provide a corporate update.
2024-02-01 02:00:00 - Press Release
Michael Austwick Joins Verona Pharma As Non-executive Director
London and raleigh, n.c., feb. 01, 2024 (globe newswire) -- verona pharma plc (nasdaq: vrna) (“verona pharma”) announces mr. michael austwick has today joined the board as a non-executive director.
Latest News
2024-04-25 02:00:00 - GlobeNewsWire
Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., April 25, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2024 on Thursday, May 9, 2024 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.
2024-03-01 08:45:00 - The Motley Fool
3 Healthcare Stocks That Have Outperformed Nvidia Since 2022
Eli Lilly has been one of the hottest names in healthcare thanks to its anti-obesity and diabetes treatments. TransMedics has been more than doubling sales and expects around 50% revenue growth this year.
2024-02-15 02:00:00 - GlobeNewsWire
Verona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quarter and full year ended December 31, 2023 on Thursday, February 29, 2024 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.
2024-01-03 02:00:00 - GlobeNewsWire
Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference
LONDON and RALEIGH, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 4:30 PM PST / 12:30 AM GMT.
2023-11-18 02:54:02 - Seeking Alpha
Verona Pharma's Ensifentrine: Potentially A New Era In Respiratory Disease Treatment
Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases. Their main candidate drug, ensifentrine, has shown promising results in clinical trials for COPD, cystic fibrosis, and asthma. The potential market for ensifentrine is significant, with millions of patients worldwide, and it could capture a significant portion of the COPD treatment market.
2023-11-08 02:00:00 - GlobeNewsWire
Verona Pharma Announces November 2023 Investor Conference Participation
LONDON and RALEIGH, N.C., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the following conferences in November 2023:
2023-11-04 11:58:02 - Seeking Alpha
Verona Pharma plc (VRNA) Q3 2023 Earnings Call Transcript
Verona Pharma plc (NASDAQ:VRNA ) Q3 2023 Results Conference Call November 2, 2023 9:00 AM ET Company Participants Dr. David Zaccardelli - CEO Mark Hahn - CFO Dr. Kathy Rickard - Chief Medical Officer Chris Martin - SVP, Commercial Conference Call Participants Andrew Tsai - Jefferies Yasmeen Rahimi - Piper Sandler Andreas Argyrides - Wedbush Securities Tom Shrader - BTIG Dipesh Patel - H.C. Wainwright Operator Welcome to Verona Pharma's Third Quarter 2023 Financial Results and Operating Highlights Conference Call.
2023-10-19 02:00:00 - GlobeNewsWire
Verona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update
LONDON and RALEIGH, N.C., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the third quarter ended September 30, 2023 on Thursday, November 2, 2023 and host an investment community conference call at 9:00 a.m. EDT / 1:00 p.m. GMT to discuss these financial results and provide a corporate update.
2023-10-04 11:17:24 - Zacks Investment Research
Down -21.27% in 4 Weeks, Here's Why Verona Pharma PLC American Depositary Share (VRNA) Looks Ripe for a Turnaround
Verona Pharma PLC American Depositary Share (VRNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
2023-10-03 02:00:00 - GlobeNewsWire
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023
PDUFA Target Action Date of June 26, 2024 Pooled analysis and subgroup data further support potential of ensifentrine, an investigational, novel, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces four presentations on additional analyses from its successful Phase 3 ENHANCE studies with ensifentrine for the treatment of chronic obstructive pulmonary disease (“COPD”) will be presented at CHEST Annual Meeting (“CHEST”) 2023.